3.b.1 Pneumococcal immunization coverage, by type of settlements

3.b.1 Pneumococcal immunization coverage, by type of settlements

3.b.1 Proportion of the target population covered by all vaccines included in their national programme

3.b Support the research and development of vaccines and medicines for the communicable and non‑communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all

Goal 3. Ensure healthy lives and promote well-being for all at all ages

Percentage of children age 12-23 months who received the third dose of Pneumococcal (Conjugate) vaccine (PCV3) at any time before the survey. 

In Serbia, active immunization against diseases caused by pneumonia has been implemented since 1 March 2018, and refers to children born from 1 January 2018.

Number of children age 12-23 months who received the third dose of Pneumococcal (Conjugate) vaccine (PCV3) at any time before the survey is divided by all children age 12-23 months and multiplied by 100.

Observation unit are children age 12-23 months.

%

Type of settlements

Republic of Serbia

Multiple Indicator Cluster Survey (MICS)

Every four years

C030b01

https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf